Compare AJANTA PHARMA with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ORCHID PHARMA LTD AJANTA PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 22.3 -0.5 - View Chart
P/BV x 3.9 0.1 3,344.0% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 AJANTA PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
ORCHID PHARMA LTD
Sep-13
AJANTA PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,422194 732.9%   
Low Rs89835 2,564.6%   
Sales per share (Unadj.) Rs233.5276.5 84.5%  
Earnings per share (Unadj.) Rs44.0-79.2 -55.5%  
Cash flow per share (Unadj.) Rs52.2-43.5 -120.0%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.153.9 472.9%  
Shares outstanding (eoy) m88.0270.45 124.9%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.00.4 1,199.2%   
Avg P/E ratio x26.4-1.4 -1,824.9%  
P/CF ratio (eoy) x22.2-2.6 -843.9%  
Price / Book Value ratio x4.52.1 214.2%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,0818,067 1,265.5%   
No. of employees `0006.82.8 242.9%   
Total wages/salary Rs m4,3072,527 170.4%   
Avg. sales/employee Rs Th3,022.66,956.1 43.5%   
Avg. wages/employee Rs Th633.4902.5 70.2%   
Avg. net profit/employee Rs Th569.1-1,993.0 -28.6%   
INCOME DATA
Net Sales Rs m20,55419,477 105.5%  
Other income Rs m211407 51.8%   
Total revenues Rs m20,76519,884 104.4%   
Gross profit Rs m5,6641,103 513.7%  
Depreciation Rs m7212,519 28.6%   
Interest Rs m125,227 0.2%   
Profit before tax Rs m5,143-6,236 -82.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,273-125 -1,016.8%   
Profit after tax Rs m3,870-5,580 -69.3%  
Gross profit margin %27.65.7 486.8%  
Effective tax rate %24.82.0 1,233.0%   
Net profit margin %18.8-28.7 -65.7%  
BALANCE SHEET DATA
Current assets Rs m11,81211,014 107.2%   
Current liabilities Rs m3,77632,060 11.8%   
Net working cap to sales %39.1-108.1 -36.2%  
Current ratio x3.10.3 910.5%  
Inventory Days Days7795 81.6%  
Debtors Days Days8234 243.2%  
Net fixed assets Rs m14,39829,440 48.9%   
Share capital Rs m175705 24.9%   
"Free" reserves Rs m22,2772,043 1,090.6%   
Net worth Rs m22,4523,800 590.9%   
Long term debt Rs m79,018 0.1%   
Total assets Rs m26,96246,510 58.0%  
Interest coverage x444.3-0.2 -230,082.9%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.80.4 182.0%   
Return on assets %14.4-0.8 -1,894.0%  
Return on equity %17.2-146.9 -11.7%  
Return on capital %23.0-3.7 -614.5%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m10,6827,513 142.2%   
Fx outflow Rs m2,1025,649 37.2%   
Net fx Rs m8,5801,865 460.2%   
CASH FLOW
From Operations Rs m3,7481,682 222.9%  
From Investments Rs m-2,228-9,860 22.6%  
From Financial Activity Rs m-1,4756,644 -22.2%  
Net Cashflow Rs m45-1,535 -2.9%  

Share Holding

Indian Promoters % 73.8 32.3 228.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.6 33.7%  
FIIs % 7.6 3.3 230.3%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.0 55.3 30.7%  
Shareholders   20,968 84,811 24.7%  
Pledged promoter(s) holding % 4.4 54.9 8.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Oct 22, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS